As promising results were obtained in preclinical analyses with antisense oligonucleotides for the treatment of non-small-cell lung carcinoma and prostate cancer [234, 235], possibility to silence EGFR and EGFRvIII gained more attention. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.